Medical Condition News

RSS

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

New results from an observational substudy from TRITON–TIMI 38 presented today at the American Heart Association (AHA) Scientific Sessions annual meeting showed that patients treated with Efient/Effient (prasugrel) prior to coronary artery bypass graft surgery (CABG) had a reduced overall mortality rate compared to patients treated with Plavix (clopidogrel)

17 Nov 2010

Study suggests cross-infection with P aeruginosa occurs between CF centers in the UK and Canada

A common transmissible strain of the bacteria Pseudomonas aeruginosa has been identified among cystic fibrosis (CF) patients in Canada, suggesting that cross-infection has occurred widely between CF centers in the United Kingdom and Canada, according to a study in the November 17 issue of JAMA. Infection with this strain among Canadian CF patients has been associated with an increased risk of death or lung transplantation.

17 Nov 2010

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

The Juvenile Diabetes Research Foundation (JDRF) and Amylin Pharmaceuticals, Inc. announced today that they entered into a research collaboration agreement to provide financial support for a clinical proof-of-concept study to investigate the effects of metreleptin, an analog of the human hormone leptin, in patients with type 1 diabetes. Researchers at The University of Texas (UT) Southwestern Medical Center will conduct the study.

17 Nov 2010

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Doctors across the United States are taking a wait-and-see approach while Congress decides whether or not to allow a scheduled 23% cut in Medicare reimbursement rates to take effect on Dec. 1.

17 Nov 2010

Researchers explore interplay between pain and anxiety

Disability from chronic pain in adolescents can be exacerbated by high levels of anxiety, according to research reported The Journal of Pain, the peer review publication of the American Pain Society.

17 Nov 2010

Study: EGFR inhibtion may help treat triple negative breast cancer

Scientists believe they may have found a new target for treating triple negative breast cancer - one of the more difficult breast cancers to treat successfully and for which there is no targeted therapy at present.

17 Nov 2010

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

AVEO Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering, developing and commercializing cancer therapeutics, today announced that it has initiated patient enrollment in an open-label, multi-center Phase 1b clinical trial evaluating tivozanib in combination with oral capecitabine (Xeloda®) in patients with certain advanced solid tumors.

17 Nov 2010

Avedro's KXL System for corneal cross-linking granted European CE Mark

Avedro, Inc., sponsor of two completed US FDA multi-center clinical trials for corneal cross-linking, today announced that its KXL™ System for performing accelerated corneal cross-linking (KXL) has received the European Union's CE Mark. The CE Mark certifies that the KXL System has met the EU's health and safety standards and opens the door to immediate commercialization across the European Economic Community and in other countries recognizing the CE Mark.

17 Nov 2010

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

ALLOZYNE Inc. announced today positive data from preclinical studies evaluating AZ17 which is a novel bispecific Th17 antagonist that inhibits the differentiation and effector function of human Th17 cells in vivo.

17 Nov 2010

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Progenics Pharmaceuticals, Inc. today announced the initiation of a phase 2 clinical trial of subcutaneous methylnaltrexone in Japan by its collaborator, Ono Pharmaceutical Co., Ltd. The drug, designated ONO-3849 in Japan, is being evaluated for the treatment of opioid-induced constipation (OIC) in patients with advanced illness such as cancer.

17 Nov 2010

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

Strokes, seizures and other neurological complications related to heart surgery account for "considerable morbidity and mortality," Loyola University Health System neurologists report in the November issue of the journal Hospital Practice.

16 Nov 2010

AEDs do not improve rate of survival for in-hospital cardiac arrests

While automated external defibrillators improve survival for out-of-hospital cardiac arrest, an analysis of data indicates their use for cardiac arrest in a hospital does not result in an improved rate of survival, according to a study in the November 17 issue of JAMA. The study is being released early online because it will be presented at the American Heart Association's annual meeting.

16 Nov 2010

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Tengion, Inc., a leader in regenerative medicine, announced today that the scheduled one-month, post-operative clinical assessment of the first implanted bladder cancer patient in its ongoing clinical trial has been completed as expected and has permitted the second patient to be enrolled without delay.

16 Nov 2010

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

Isis Pharmaceuticals, Inc. and Xenon Pharmaceuticals Inc. announced today a new collaboration to discover and develop antisense drugs as novel treatments for the common disease anemia of inflammation (AI).

16 Nov 2010

Omron supports American Heart Association's educational initiatives for hypertension treatment

Omron Healthcare today announced support for the American Heart Association's broad-based healthcare awareness campaign that will educate providers on hypertension treatment recommendations, including home blood pressure monitoring and best practices for integrating this into their standard of care.

16 Nov 2010

FDA grants Impax final approval for generic Allegra-D ANDA

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted final approval of the Company's Abbreviated New Drug Application (ANDA) for the generic version of Allegra-D® (Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride Extended-release) 60mg/120mg tablets. The Company is preparing for product launch through Global Pharmaceuticals, Impax's generic division.

16 Nov 2010

Clinical Data receives U.S. patent for vilazodone

Clinical Data, Inc. today announced the issuance of U.S. Patent No. 7,834,020 claiming the polymorphic form of vilazodone (vilazodone HCl, Form IV), a compound currently in development for the treatment of Major Depressive Disorder.

16 Nov 2010

Urgent need for bowel cancer screening funding

Bowel Cancer Foundation chairman, Graham Newstead feeling frustrated at the federal government’s indecision on bowel cancer screening funds has expressed his dismay. He suggested that the government should ensure the future funding for the screening test that has saved an estimated 11,000 lives since screening was introduced in 2006.

16 Nov 2010

Gore REDUCE Clinical Study investigates PFO in stroke patients

W. L. Gore & Associates today joined the US principal investigators for the Gore REDUCE Clinical Study in reaffirming their commitment to the study of Patent Foramen Ovale (PFO) in stroke patients using the GORE HELEX Septal Occluder.

16 Nov 2010

Synexus to develop effective clinical trials for Mild cognitive impairment

Mild cognitive impairment (MCI) is under the pharma' spotlight as the number of clinical trials currently underway has increased significantly during the past 12 months and the search for treatments that will prevent the progression of MCI to dementia continues. Synexus has teamed up with dementia expert, Dr Roger Bullock, to develop more effective clinical trials for this field.

From AES - Accelerated Enrollment Solutions 16 Nov 2010

Medical Condition News

TRITON–TIMI 38 substudy shows prasugrel reduces overall mortality rate in ACS patients

Study suggests cross-infection with P aeruginosa occurs between CF centers in the UK and Canada

JDRF, Amylin collaborate to support metreleptin study for type 1 diabetes

Medicare roundup: Payment cuts irk healthcare industry; officials mull new prostate-cancer treatment

Researchers explore interplay between pain and anxiety

Study: EGFR inhibtion may help treat triple negative breast cancer

AVEO commences enrollment in Phase 1b combination trial of tivozanib with oral capecitabine in advanced tumors

Avedro's KXL System for corneal cross-linking granted European CE Mark

ALLOZYNE's AZ17 antagonist shows positive data for treatment of autoimmune diseases

Progenics initiates ONO-3849 phase 2 clinical trial for OIC in Japan

Neurologic complications remain an important cause of morbidity and mortality after heart surgeries

AEDs do not improve rate of survival for in-hospital cardiac arrests

Tengion permits second patient enrollment in Neo-Urinary Conduit for bladder cancer

Isis, Xenon enter collaboration to discover and develop antisense drugs for AI

Omron supports American Heart Association's educational initiatives for hypertension treatment

FDA grants Impax final approval for generic Allegra-D ANDA

Clinical Data receives U.S. patent for vilazodone

Urgent need for bowel cancer screening funding

Gore REDUCE Clinical Study investigates PFO in stroke patients

Synexus to develop effective clinical trials for Mild cognitive impairment

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News